Needham Rates Viridian Therapeutics (VRDN) buy, $34 Price Target

Analyst Serge Belanger maintains a buy rating on Viridian Therapeutics, keeping a $34 price target as the biotech firm advances its rare disease treatments, a 80.95% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 6:00 AM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Needham rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $34 price target on June 30, 2026.

Since the rating, $VRDN is up 11.4% after 1 week, up 8.3% after 1 month and up 3.6% to date (from the $18.37 close on Jun 30, 2026).

VRDN Viridian Therapeutics, Inc.

$19.03 -37.97% year to date

Daily close · Oct 16, 2026

Key Points

Needham analyst Serge Belanger reiterated a buy rating on Viridian Therapeutics (NasdaqCM: VRDN) on June 30, 2026, maintaining a $34 price target.
Needham's $34 price target implies 80.95% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.79 share price.
The stock traded at $18.79 on Tuesday, sitting well below its 52-week high of $34.29 and near its low of $13.18.
Wall Street maintains an overall positive view on the stock, backed by 16 analyst opinions and a mean price target of $36.62.

Get $VRDN trade alerts by text

We text you when insiders, Congress or big funds trade $VRDN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures

Needham Reaffirms Outlook on Viridian Therapeutics

Needham analyst Serge Belanger kept a buy rating on Viridian Therapeutics, Inc. (NasdaqCM: VRDN) on June 30, 2026, holding the firm's price target at $34. That stance aligns with a wider wave of positive analyst attention hitting the biotechnology company around the same time. While some peers adjusted their targets higher during late June and August, Needham's $34 target offers a clear window into how the firm views the company's long-term drug development pipeline.

Analyst rating track record

Needham vs. the S&P 500

YTD return +17.96% hypothetical

All-time return +87.96% S&P 500 +27.66%

vs. S&P 500 +60.30% ahead of the index

Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.

Stock Performance and Market Position

Viridian Therapeutics shares changed hands at $18.79 on Tuesday. The stock has experienced a wide trading range over the past year, hitting a 52-week low of $13.18 and climbing as high as $34.29. Its 50-day moving average sits at $21.66, while the 200-day moving average rests at $23.36. With a market capitalization of about $2.44 billion, the company trades below its longer-term trend lines as investors weigh its ongoing clinical trials.

12-month forecast

$VRDN price target

Viridian Therapeutics, Inc. daily closes and this analyst's $34 target. Not advice.

Analysts Set New Price Targets

Needham's rating is part of a broader group of recent updates from major financial firms covering the biotechnology developer. On June 30, 2026, RBC Capital maintained its Outperform rating while raising its price target to $35 from $34. Truist Securities also maintained a Buy rating on June 30, 2026, lifting its target to $38 from $35, and Wedbush maintained an Outperform rating with a higher target of $43. Earlier, on June 29, 2026, Wells Fargo upgraded the stock to Overweight with a $31 target. Across 16 analyst opinions tracked by the market, the consensus view leans positive, with a mean price target of $36.62, ranging from a low of $22 up to a high of $50.

Inside Viridian Therapeutics

Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. The firm focuses on discovering and developing treatments for serious and rare diseases, with a core emphasis on thyroid eye disease and Graves' disease. Its pipeline features antibody therapies designed to target IGF-1R and neonatal Fc receptors. Because the company is still in the development phase and is not yet profitable, it carries a negative forward P/E ratio, while holding substantial liquidity with current and quick ratios well above 16.

What to Watch at VRDN

Investors will look toward the company's next earnings report, scheduled for November 5, 2026, for further updates on clinical trial milestones and cash burn. Additional analyst revisions and trial data readouts will also shape how the market values the stock moving forward.